Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notice to Readers: Additional Options for Preventive Treatment for Persons Exposed to Inhalational Anthrax

Many persons who were exposed to inhalational anthrax in the recent bioterrorism-related anthrax attacks have or are concluding their 60-day course of antimicrobial prophylaxis. Some persons, especially those who were exposed to high levels of anthrax spores, might want to take additional precautions. The U.S. Department of Health and Human Services (DHHS) is providing two additional options beyond the 60-day anti-microbial prophylaxis course: an extended 40-day course of antimicrobial prophylaxis and investigational postexposure treatment with anthrax vaccine.

The three preventive options for persons with risks for inhalational anthrax are 1) 60 days of antimicrobial prophylaxis, accompanied by monitoring for illness; 2) 40 additional days of antimicrobial prophylaxis (intended to provide protection against the theoretical possibility that anthrax spores might cause illness up to 100 days after exposure) accompanied by monitoring for illness or adverse reactions; and 3) 40 additional days of anti-microbial prophylaxis plus 3 doses of anthrax vaccine administered over a 4-week period. Although not a use approved by the Food and Drug Administration, the vaccine might provide additional protection by inducing an immune response to Bacillus anthracis. As an investigational new drug, the vaccine should be administered with informed consent, and vaccinated persons may participate in a follow-up evaluation measuring the effect of the vaccine when administered after exposure.

Additional information about these options is available from DHHS at http://www.hhs.gov/news/press/2001pres/20011218.html.



Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #